A Registry Study of Patients Hospitalized With Confirmed COVID-19

Capital Medical University

Status: Not yet enrolling

Conditions: COVID-19

Treatments: Drug: paxlovid; Drug: No paxlovid; Drug: Paxlovid

Study type: Observational

Funder types: Other

Identifiers

NCT05792865

CYH-PHARM1

Details and patient eligibility

About

The design of this registered study aims to evaluate the efficacy and safety of Paxlovid in the treatment of hospitalized COVID-19 patients, and to explore factors related to the efficacy and safety of Paxlovid.

Enrollment: 488 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Confirmed diagnosis of COVID-19 infection.
2. Presence of at least one high-risk factor, including age ≥60 years, diabetes, hypertension, cardiovascular disease, stroke, chronic liver or kidney disease, cancer, history of smoking or obesity.

Exclusion criteria

• No specific exclusion criteria in this study.

Trial design

488 participants in 3 patient groups

Paxlovid（Within 5 days after the diagnosis of COVID-19）

Description:

According to the patient's medical records, the time from the diagnosis of COVID-19 to the prescription of PAXLOVID is within 5 days.

Treatment:

Drug: paxlovid

Paxlovid （More than 5 days after the diagnosis of COVID-19）

Description:

According to the patient's medical records, the time from the diagnosis of COVID-19 to the prescription of PAXLOVID exceeds 5 days.

Treatment:

Drug: Paxlovid

No paxlovid used

Description:

Patients have never used Paxlovid after being diagnosed with COVID-19, whether before or after hospitalization.

Treatment:

Drug: No paxlovid